Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150
CANO.WS
CANO.WS was delisted on the 9th of November, 2023.
33 hedge funds and large institutions have $16.7M invested in Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
14% more funds holding
Funds holding: 29 → 33 (+4)
36% less capital invested
Capital invested by funds: $26.3M → $16.7M (-$9.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
+$1.02M |
| 2 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
+$562K |
| 3 |
ICM
Ionic Capital Management
New York
|
+$448K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$319K |
| 5 |
D.E. Shaw & Co
New York
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$309K |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$306K |
| 3 |
Barclays
London,
United Kingdom
|
-$201K |
| 4 |
BlackRock
New York
|
-$23.9K |
| 5 |
TCA
Taconic Capital Advisors
New York
|
-$10.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RA
26
Royce & Associates
New York
| $34K | – | – | – |
|
|
SC
27
Shay Capital
New York
| $27K | +$41.3K | +39,825 | New |
|
|
VF
28
Virtu Financial
New York
| $26K | +$39K | +37,636 | New |
|
|
AAI
29
Aequim Alternative Investments
Mill Valley,
California
| $25K | – | – | – |
|
|
BCM
30
Bluefin Capital Management
New York
| $14K | +$182 | +176 | +0.9% |
|
31
Morgan Stanley
New York
| $1K | – | – | – |
|
32
UBS Group
Zurich,
Switzerland
| $1K | +$49 | +47 | +4% |
|
CANO.WS Hedge Fund Activity: Q2 2022 in Review
33 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 (CANO.WS) for Q2 2022, worth a combined $16.7M — down 36% from $26.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANO.WS positions and 1 closed out — a net gain of 4 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Josh Arnold Investment Consultant, opening a new position worth an estimated $1.02M. The largest seller was Aristeia Capital, cutting an estimated $309K.
- 33 institutional investors held Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 (CANO.WS) as of Q2 2022, up from 29 in Q1 2022.
- Funds reported $16.7M of Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 stock for Q2 2022, down 36% quarter-over-quarter.
- 5 funds opened new Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 positions in Q2 2022 and 1 closed out, a net change of +4 holders.
- The largest Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 buyer in Q2 2022 was Josh Arnold Investment Consultant, an estimated $1.02M added.
- The largest Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 seller in Q2 2022 was Aristeia Capital, an estimated $309K sold.
Based on aggregated 13F filings for Q2 2022.